History

TG Timeline

icon-1.png

Happy B-Day TG!

images/tgbdayweb.jpg

We celebrate our 13th Anniversary with our own symposium, “optics, algos & ice @ the very top* the ultimate cryocut”, which may also be considered as a major marketing event this year. TG has been achieved over those years: ISO 13485 certificate! Installations in 28 countries on 6 continents! 560+ reference publications! This year we are expanding our activities in Asia (China, Singapore, India), South America (Brazil), South Africa, and Middle East/Gulf (Israel, Kuwait, Iran)! HAPPY B-DAY and thank you to the global TG-team!

November 2016
icon-1.png

1st Place in the International Scanner Contest

images/Certificate-ISC-2016web.jpg

TG wins first place in the Image Analysis category at the International Scanner Contest 2016. TissueGnostics recently also delivered and validated the first TissueFAXS Confocal system using the Crest Optics X Light V2 Confocal Imager.

September 2016
icon-1.png

EU FUND

images/euFlagweb.jpg

CaSR - Biomedicine and ALKATRAS are two EU projects, which are fund by the EU. They are both Marie-Sklodowska-Curie training programs.

2015
icon-1.png

FOUNDATION TG-CHINA DIVISION

images/tgchinaweb2.jpg

“TissueGnostics China Division” is not a legal body of its own (like TG-USA or TG-RO) but a joint endeavor between TissueGnostics Austria and Beijing Huawei Zhongyi Technology. It embodies a functional entity that represents the brand “TissueGnostics” in the China marketplace in a way, which much better meets the demands and expectations of customers in China.

2014
icon-1.png

TG ALL OVER THE WORLD

images/welt2.jpg

Active sales in more than 30 countries world wide.

2010
icon-1.png

IVD DECLARATION

images/tv.jpg

In-Vitro Diagnostics (IVD) declaration of all TG-products. TissueGnostics is an EN ISO 13485:2003 certified Austrian Medical Technology company focusing on image analysis.

2009
icon-1.png

PRODUCT LAUNCH HemoFAXS

images/hemofaxsweb.jpg

HemoFAXS is a CE-IVD ISO 13 485 conform complete solution for clinical routine hematology. It offers fully automated classification of leukocytes and erythrocytes in peripheral blood and body fluid. A bone marrow application as well as an application for veterinary medicine is also available. FDA approval is in progress.

2008
icon-1.png

FOUNDATION TG-USA

images/tgusaweb3.JPG

Foundation of TissueGnostics USA Inc., product launch HistoFAXS and purchase of TissueGnostics Romania.

2007
icon-1.png

PRODUCT LAUNCH TissueFAXS 1.0

images/tissuefaxsplusweb.jpg

Automated identification and functional characterization of single cells in tissue sections. In contrast to morphometry, which provides values referring to the metric dimensions of cells, the term “tissue cytometry” refers to quantification of molecular parameters. Though methodically different, tissue cytometry exhibits a functional similarity to flow cytometry. While flow cytometer is restricted to cells in suspension (e.g. blood) and cannot be applied to solid tissue, tissue cytometry refers to the cytometric analysis (as opposed to morphometric analysis) of histological sections. TissueGnostics has been the first manufacturer of tissue cytometers offering a flow cytometry-like workflow (but applied to tissue sections).

2006
icon-1.png

FOUNDATION & COOPERATION WITH LBI-CR

images/lbi.gif

Foundation of TG-Romania and cooperation with Ludwig Boltzmann Institute for Cancer Research, Vienna, which is focused on basic cancer research to establish molecular insight into the complex disease mechanisms.

2005
icon-1.png

START OF SOFTWARE DEVELOPMENT

images/swdweb1.jpg

Start of TissueQuest and HemoFAXS software-development.

2004
icon-1.png

FOUNDATION OF TG-VIENNA, AUSTRIA

images/tgceoweb1.jpg

TissueGnostics was established in 2003 after nearly a decade of basic research. The goal was to supply scientists with qualitative and observer independent results for cell and tissue analysis in tissue context and this in automated format and significantly less time. Katja Österreicher, Georg Steiner and Dr. Rupert Ecker, the three co-founders of the company, with the aid of a dozen of development partners (Medical University Vienna, Memorial Sloan-Kettering Cancer Center New York, Ludwig Boltzmann Institute for Cancer Research, Vienna; Fred Hutchinson Cancer Center, Seattle; Brighamand Women`s Hospital, Boston; etc.) succeeded in reaching this target by 2005.

2003
zh cn